# Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

> **NCT07224841** · — · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 500 (estimated)

## Conditions studied

- CRC (Colorectal Cancer)

## Interventions

- **DIAGNOSTIC_TEST:** cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase)
- **DIAGNOSTIC_TEST:** EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)

## Key facts

- **NCT ID:** NCT07224841
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2026-06-18
- **Final completion:** 2026-06-18
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224841, "Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07224841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*